Please enable JavaScript in your browser. 
Skip to main content
Drug Information Portal National Library of Medicine
       Home    Substance
Drug Name: AMG 139
Description: Targets interleukin-23; for treatment of Crohn's disease; in phase II clinical trials (2015).

Amgen: AMG 139 is a human monoclonal antibody that neutralises IL-23 interaction with its receptor while sparing IL-12. It is being investigated as a treatment for a variety of inflammatory disorders. AMG 139 is being investigated in Phase 1 for Crohns disease, with lifecycle possibilities in psoriasis and other inflammatory conditions. (Manufacturer) 

Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
Drug Information Portal Mobile Site
Last updated: Apr 2019